Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up of CHC Subjects After SVR with DAAs
NCT03520660Phase 4Active, not recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Oct 2018
- Primary completion
- Dec 2032
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of sofosbuvir + velpatasvir in hepatitis C (HCV), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Oct 2018; status: active, not recruiting.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03520660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520660.